US/UK/Canada

Share

Pick a time period -
Tags ( Active)

New distributor for Germany and new chairman in Likvor

The medical device company Likvor AB strengthens its competences with a new chairman of the board, Stefan Sallerfors. Sallerfors has a background as doctor and specialist in medical radiology and has been CEO for GE Medical System Sverige AB and Helsingborg hospital. In November Likvor continues the expansion on the European market with a new distribution agreement for the German market. The unique LIKVOR CELDA® SYSTEM is therefore available in Germany, Austria and Switzerland through the new distributor, Neuromed. The system helps to restore normal life back to millions of dementia patients

Likvor goes - UK

The unique LIKVOR CELDA® SYSTEM is now available on the UK market and the first system has been sent to a customer. In addition, Likvor AB has signed a distribution agreement with its first distributor for this region.  The system helps to restore normal life back to millions of dementia patients with hydrocephalus diagnosis.Likvor AB takes an important step out on the European market by signing a distribution agreement for the UK market with Seren Medical Ltd. Seren Medical is a company specializing in sales, marketing, service and support of state-of-the-art medical equipment. LIKVOR

Likvor continues to strengthen its sales organization

Likvor AB is pleased to announce the appointment of Dr. Hadi Ghane, as Sales Director to our team.  As “Sales Director”, Dr. Ghane will be responsible for the sales activities of Likvors current product portfolio, the LIKVOR CELDA® SYSTEM.  Dr. Ghane will be a valuable contributor to and be an active part in the team to build up and prepare the company for future growth and expansion.Dr Hadi Ghane brings with him 13 years of experience within Biotech and Healthcare industry where he has recently held the position as Sales Director at Beampoint AB. Prior to Beampoint; he has held a variety

First LIKVOR CELDA system delivered to Finland

Kuopia University Hospital increases their possibility to diagnose and treat Normal Pressure Hyrocephalus (NPH).  Likvor has delivered its first LIKVOR CELDA® system to Kuopio University Hospital in Finland. The system will be installed at the department of Neurosurgery.With LIKVOR CELDA® system the Kupio University Hospital will be able to measure the dynamics of the most important parameters concerning the patients’ cerebrospinal fluid including pressure and flow in a controlled and safe process. LIKVOR CELDA® system was developed to facilitate greater understanding and enhance diagnosis

Likvor receives an order for CELDA from Uppsala University Hospital

Likvor has received an order for Likvor CELDA™ from Uppsala University Hospital (Akademiska Universitetssjukhuset). With Likvor CELDA™ the clinical will be able to dynamic measure the most important parameters concerning the patients’ cerebrospinal fluid including pressure and flow. Likvor CELDA™ was developed to facility greater understanding and enhancing diagnosis of normal pressure hydrocephalus (NPH), a condition that is often mistaken for dementia. This is the second order for the instrument; the fist came from Norrlands Universitetssjukhus, Umeå.Likvor CELDA™ is the first

Likvor’s technology supports the diagnosis of hidden disease

Likvor, a Swedish medical device start-up company, has been granted CE marking for its instrument for better and safer identification and diagnosis of Normal Pressure Hydrocephalus (NPH). The instrument, CELDA(TM), was developed to assess the dynamics – pressure, flow and resistance – of cerebrospinal fluid (CSF) surrounding the brain and spinal cord. CELDA facilities greater understanding and enhanced diagnosis of NPH, a condition that is often mistaken for dementia. CE marking opens up the European market for the product.CELDA(TM) is the first commercially approved instrument for

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Media